Institut Für Klinische Krebsforschung Ikf Gmbh At Krankenhaus Nordwest
Clinical trials sponsored by Institut Für Klinische Krebsforschung Ikf Gmbh At Krankenhaus Nordwest, explained in plain language.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- Experimental cancer combo aims to supercharge immune attack on tumors Results expected Sep 2026 (estimated)
- Double immunotherapy combo aims to boost lung cancer surgery outcomes Results expected Dec 2026 (estimated)
- New cocktail targets HER2-Positive bile duct cancer in small trial Results expected Dec 2026 (estimated)
- Aiming to cure esophageal cancer without the knife Results expected Jan 2027 (estimated)
- Heat and immunotherapy join forces against bile duct cancer Results expected Jan 2027 (estimated)
-
Cancer gene hunt: could tumor maps guide better GI cancer treatment?
Knowledge-focused Stopped earlyThis study looked at genetic mutations in tumors from 565 people with advanced gastrointestinal cancers, including liver, bile duct, gallbladder, pancreas, esophagus, and stomach cancers. The goal was to see how often these mutations could be targeted by existing drugs and to tra…
Sponsor: Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest • Aim: Knowledge-focused
Last updated Jun 27, 2026 09:02 UTC
-
Sarcoma patients share their experience on a second chemo round
Knowledge-focused Stopped earlyThis study aimed to track how soft tissue sarcoma patients feel—symptoms, side effects, and quality of life—when they receive trabectedin chemotherapy again after a break. Only 7 patients were enrolled before the study was stopped early. The goal was to gather real-world patient …
Sponsor: Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:00 UTC